Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer (HFS)

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of malignancy-related mortality. Capecitabine has been approved for the treatment of colorectal cancer as first-line therapy. About 50%-68% of patients who take capecitabine develop Hand-foot syndrome. Hand-foot syndrome (HFS) is the most common adverse event of capecitabine-based chemotherapy. Initial symptoms of HFS are dysesthesia, tingling in the palms, fingers, and soles of the feet, and erythema, which may progress to an extremely painful and debilitating condition without prompt management. These symptoms can potentially lead to a worsened quality of life in patients taking capecitabine-based chemotherapy. Moreover, the adverse reaction necessitates dose-reduction or withdrawal of the chemotherapeutic agent. The mechanisms of HFS are still unknown, and there are limited data available on how to prevent them or manage them. However, different hypotheses of capecitabine-induced HFS pathogenesis have been suggested. One of the hypotheses stated that HFS is a kind of inflammation mediated by cyclooxygenase's (COX-2) over expression in palm and feet by capecitabine and its metabolites causing elevation of inflammatory markers as tumor necrosis factor alpha (TNF-α). COX-2 enzyme plays a main role in inflammation and pain. Therefore, celecoxib which is selective (COX-2) inhibitor may have a key role in the HFS treatment plan. A retrospective study and two prospective studies showed that combining capecitabine with celecoxib, a selective COX-2 inhibitor, can significantly reduce capecitabine-related HFS in colorectal cancer patients. Those studies were dependent on HFS grading only without measuring any markers. So, in our study we assess possible protective effect of celecoxib against capecitabine induced HFS and measure inflammatory marker as tumor necrosis factor alpha (TNF-α), oxidative stress marker as Malondialdehyde (MDA), and cyclooxygenase-2 (COX-2) enzyme to show whether capecitabine induced HFS is caused by COX-2 mediated inflammation or not.

Study Overview

• Status: Recruiting
• Conditions: Colorectal Cancer; Hand and Foot Syndrome; Erythrodysesthesia Syndrome; HFS
• Intervention / Treatment: Drug: Celecoxib 200mg; Drug: Capecitabine-based chemotherapy

• Study Type: Interventional
• Enrollment (Anticipated): 44
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Ahmed Mohamed Kettana; Phone Number: +201009241434; Email: ahmed150848@pharm.tanta.edu.eg
• Study Contact Backup: Name: Tarek Mohamed Mostafa, Professor of clinical pharmacy; Phone Number: +201154594035; Email: tarek.mostafa@pharm.tanta.edu.eg

Study Locations

• Egypt
  • Tanta, Egypt
    • Recruiting
    • Faculty of Pharmacy-Tanta University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria:

• Age: 18-65 years old.
• Gender: Male and female.
• Newly diagnosed colorectal cancer patients who are scheduled to receive capecitabine-based chemotherapy.
• Eastern Cooperative Oncology Group (ECOG) performance status < 2
• Patients with adequate renal function (Sr. creatinine < 1.2 mg/dl or eGFR ≥ 90 ml/min).
• Patients with adequate hepatic function (Sr. bilirubin < 1.2 mg/dl).

Exclusion criteria:

• Pregnant and lactating females.
• Patients with cardiovascular disease (congestive heart failure, cardiac arrhythmia, or coronary artery disease, …. etc.).
• History of H-Pylori infection.
• Patients with a known hypersensitivity to any of the used drugs.
• Patients with any contraindication to any of the used drugs.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Celecoxib arm; This arm will include 22 patients who will receive 6 cycles of capecitabine-based chemotherapy (cycle is every 3 weeks) in addition to 200 mg of oral celecoxib twice daily for 14 days of the 3-week cycle. The study duration will be the duration of the 6 cycles.	Drug: Celecoxib 200mg; 200 mg of oral celecoxib twice daily for 14 days of the 3-week cycle.; Drug: Capecitabine-based chemotherapy; Capecitabine-based chemotherapy
Placebo Comparator: Control arm; This arm will include 22 patients who will receive 6 cycles of capecitabine-based chemotherapy (cycle is every 3 weeks).	Drug: Capecitabine-based chemotherapy; Capecitabine-based chemotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The change in HFS grading.	The change in hand and foot syndrome (HFS) grading according to common terminology criteria of adverse events (CTCAE) version 5.0.	After each cycle (each cycle is 21 days).
The change in HFS-specific QOL questionnaire (HFS-14).	Assessment of patients' quality of life using HFS-specific QOL questionnaire (HFS-14) based on patients' symptoms.	After each cycle (each cycle is 21 days).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The change in serum levels of cyclooxygenase-2 (COX-2) enzyme.	The change in serum levels of cyclooxygenase-2 (COX-2) enzyme.	At basline and after the sixth cycle (each cycle is 21 days).
The change in serum levels of tumor necrosis factor alpha (TNF-α).	The change in serum levels of tumor necrosis factor alpha (TNF-α) as a inflammatory marker.	At basline and after the sixth cycle (each cycle is 21 days).
The change in serum levels of malondialdehyde (MDA).	The change in serum levels of malondialdehyde (MDA) as oxidative stress marker.	At basline and after the sixth cycle (each cycle is 21 days).

Collaborators and Investigators

• Sponsor: Tanta University

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2022
• Primary Completion (Anticipated): April 1, 2024
• Study Completion (Anticipated): April 1, 2025

Study Registration Dates

• First Submitted: April 1, 2022
• First Submitted That Met QC Criteria: April 7, 2022
• First Posted (Actual): April 14, 2022

Study Record Updates

• Last Update Posted (Actual): April 14, 2022
• Last Update Submitted That Met QC Criteria: April 7, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Keywords: Colorectal Cancer; Hand and Foot Syndrome; HFS; capecitapine induced hand and foot syndrome; Erythrodysesthesia Syndrome; capecitabine based chemotherapy
• Additional Relevant MeSH Terms: Chemically-Induced Disorders; Digestive System Diseases; Pathologic Processes; Skin Diseases; Neoplasms; Neoplasms by Site; Disease; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Dermatitis; Drug-Related Side Effects and Adverse Reactions; Drug Eruptions; Drug Hypersensitivity; Syndrome; Colorectal Neoplasms; Hand-Foot Syndrome; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclooxygenase Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Cyclooxygenase 2 Inhibitors; Capecitabine; Celecoxib
• Other Study ID Numbers: 42022

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No